|
1.
|
Goldstein SR: Controversy about uterine
effects and safety of SERMs: the saga continues. Menopause.
9:381–384. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Mourits MJ, De Vries EG, Willemse PH, Ten
Hoor KA, Hollema H and Van der Zee AG: Tamoxifen treatment and
gynecologic side effects: a review. Obstet Gynecol. 97:855–866.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Katzenellenbogen JA, O’Malley BW and
Katzenellenbogen BS: Tripartite steroid hormone receptor
pharmacology: interaction with multiple effector sites as a basis
for the cell- and promotor-specific action of these hormones. Mol
Endocrinol. 10:119–131. 1996.
|
|
4.
|
Osborne CK and Schiff R: Estrogen-receptor
biology: continuing progress and therapeutic implications. J Clin
Oncol. 23:1616–1622. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Shang Y and Brown M: Molecular
determinants for the tissue specificity of SERMs. Science.
295:2465–2468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Gielen SC, Kühne LC, Ewing PC, Blok LJ and
Burger CW: Tamoxifen treatment for breast cancer enforces a
distinct gene-expression profile on the human endometrium: an
exploratory study. Endocr Relat Cancer. 12:1037–1049. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
de Cremoux P: Hormone therapy and breast
cancer. Bull Cancer. 98:1311–1319. 2011.(In French).
|
|
8.
|
Gielen SC, Santegoets LA, Hanifi-Moghaddam
P, Burger CW and Blok LJ: Signaling by estrogens and tamoxifen in
the human endometrium. J Steroid Biochem Mol Biol. 109:219–223.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Curtis RE, Boice JD Jr, Shriner DA, Hankey
BF and Fraumeni JF Jr: Second cancers after adjuvant therapy for
breast cancer. J Natl Cancer Inst. 88:832–834. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Deligdisch L, Kalir T, Cohen CJ, de Latour
M, Le Bouedec G and Penault-Llorca F: Endometrial histopathology in
700 patients treated with tamoxifen for breast cancer. Gynecol
Oncol. 78:181–186. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Fisher B, Constantino JP, Redmond CK,
Fisher ER, Wickerham DL and Cronin WM: Endometrial cancer in
tamoxifen-treated breast cancer patients: findings from the
National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J
Natl Cancer Inst. 86:527–537. 1994. View Article : Google Scholar
|
|
12.
|
Maugeri G, Nardo LG, Campione C and Nardo
F: Endometrial lesions after tamoxifen therapy in breast cancer
women. Breast J. 7:240–244. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Mignotte H, Lasset C, Bonadona V, et al:
Iatrogenic risk of endometrial carcinoma after treatment for breast
cancer in a large French case-control study. Fédération Nationale
des Centres de Lutte Contre le Cancer (FNCLCC). Int J Cancer.
76:325–330. 1998.PubMed/NCBI
|
|
14.
|
Van Leeuwen FE, Benraadt J, Coebergh JW,
et al: Risk of endometrial cancer after tamoxifen treatment of
breast cancer. Lancet. 343:448–452. 1994.PubMed/NCBI
|
|
15.
|
Dibi RP, Zettler CG, Pessini SA, Ayub AV,
de Almeida SB and da Silveira GP: Tamoxifen use and endometrial
lesions: hysteroscopic, histological, and immunohistochemical
findings in postmenopausal women with breast cancer. Menopause.
16:293–300. 2009. View Article : Google Scholar
|
|
16.
|
Marttunen MB, Cacciatore B, Hietanen P,
Pyrhönen S, Tiitinen A, Wahlström T and Ylikorkala O: Prospective
study on gynaecological effects of two antioestrogens tamoxifen and
toremifene in postmenopausal women. Br J Cancer. 84:897–902. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Belisário MS, Vassallo J, Andrade LA,
Alvarenga M, Pinto GA and Monteiro IM: The expression of the
hormone receptors in the endometrium and endometrial polyps in
postmenopausal women and its relationship to body mass index.
Maturitas. 53:114–118. 2006.PubMed/NCBI
|
|
18.
|
Inceboz US, Nese N, Uyar Y, et al: Hormone
receptor expressions and proliferation markers in postmenopausal
endometrial polyps. Gynecol Obstet Invest. 61:24–28. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Sant’Ana de Almeida EC, Nogueira AA, et
al: Immunohistochemical expression of estrogen and progesterone
receptors in endometrial polyps and adjacent endometrium in
postmenopausal women. Maturitas. 49:229–233. 2004.
|
|
20.
|
Lopes RG, Baracat EC, de Albuquerque Neto
LC, Ramos JF, Yatabe S, Depesr DB and Lippi UG: Analysis of
estrogen- and progesterone-receptor expression in endometrial
polyps. J Minim Invasive Gynecol. 14:300–303. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Cohen I, Beyth Y, Altaras MM, et al:
Estrogen and progesterone receptor expression in postmenopausal
tamoxifen-exposed endometrial pathologies. Gynecol Oncol. 67:8–15.
1997. View Article : Google Scholar
|
|
22.
|
McGurgan P, Taylor LJ, Duffy SR and
O’Donovan PJ: Does tamoxifen therapy affect the hormone receptor
expression and cell proliferation indices of endometrial polyps? An
immunohistochemical comparison of endometrial polyps from
postmenopausal women exposed and not exposed to tamoxifen.
Maturitas. 54:252–259. 2006. View Article : Google Scholar
|
|
23.
|
Mourits MJ, Ten Hoor KA, van der Zee AG,
Willemse PH, de Vries EG and Hollema H: The effects of tamoxifen on
proliferation and steroid receptor expression in postmenopausal
endometrium. J Clin Pathol. 55:514–519. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Schwartz LB, Krey L, Demopoulos R,
Goldstein SR, Nachtigall LE and Mittal K: Alterations in steroid
hormone receptors in the tamoxifen-treated endometrium. Am J Obstet
Gynecol. 176:129–137. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Fons G, Hasibuan SM, van der Velden J and
ten Kate FJ: Validation of tissue microarray technology in
endometrioid cancer of the endometrium. J Clin Pathol. 60:500–503.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Harvey JM, Clark GM, Osbome CK and Allred
DC: Estrogen receptor status by immunohistochemistry is superior to
the ligand-binding assay for predicting response to adjuvant
endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481.
1999.
|
|
27.
|
Holm S: A simple sequentially rejective
multiple test procedure. Scand J Stat. 6:65–70. 1979.
|
|
28.
|
Shaffer JP: Multiple hypothesis testing.
Ann Rev Psychol. 46:561–584. 1995. View Article : Google Scholar
|
|
29.
|
Elkas J, Armstrong A, Pohl J, Cuttitta F,
Martínez A and Gray K: Modulation of endometrial steroid receptors
and growth regulatory genes by tamoxifen. Obstet Gynecol.
95:697–703. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Corley D, Rowe J, Curtis MT, Hogan WM,
Noumoff JS and Livolsi VA: Postmenopausal bleeding from unusual
endometrial polyps in women on chronic tamoxifen therapy. Obstet
Gynecol. 79:111–116. 1992.PubMed/NCBI
|
|
31.
|
Kennedy MM, Baigrie CF and Manek S:
Tamoxifen and the endometrium: review of 102 cases and comparison
with HRT-related and non-HRT-related endometrial pathology. Int J
Gynecol Pathol. 18:130–137. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Green S and Chambon P: Nuclear receptors
enhance our understanding of transcription regulation. Trends
Genet. 4:309–314. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Parker MG, Fawell SE, Lees JA, White R,
Emmans CE and Danielian P: Function of estrogen receptor as a
transcription factor: A target for antiestrogens. Origins of Human
Cancer: A Comprehensive Review. Brugge J, Curran E and McCormick F:
Cold Spring Harbor Laboratory Press; Cold Spring Harbor: pp.
667–674. 1991
|
|
34.
|
Brys M, Szyllo K, Romanowicz-Makowska H,
Dobrowolski Z, Maslowska I and Krajewska W: Expression of estrogen
and progesterone receptor genes in endometrium, myometrium and
vagina of postmenopausal women treated with estriol. Sao Paulo Med
J. 127:128–133. 2009.PubMed/NCBI
|
|
35.
|
Turashvili G, Leung S, Turbin D, et al:
Inter-observer reproducibility of HER2 immunohistochemical
assessment and concordance with fluorescent in situ hybridization
(FISH): pathologist assessment compared to quantitative image
analysis. BMC Cancer. 9:1652009. View Article : Google Scholar
|
|
36.
|
Turbin DA, Leung S, Cheang MC, et al:
Automated quantitative analysis of estrogen receptor expression in
breast carcinoma does not differ from expert pathologist scoring: a
tissue microarray study of 3,484 cases. Breast Cancer Res Treat.
110:417–426. 2008. View Article : Google Scholar
|
